by administration of oritavancin

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9220749
APP PUB NO 20140100157A1
SERIAL NO

14101645

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MELINTA THERAPEUTICS INC300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baines, Simon Leeds, GB 3 3
Lehoux, Dario Terrebonne, CA 7 14
Parr, Thomas R Indianapolis, US 10 69
Wilcox, Mark Harvey Leeds, GB 3 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 29, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00